3D Medicines Nabs RMB 1.5 Billion Financing

The leading company of molecular diagnostics platform 3D Medicines (3DMed) announced the completion of a new round of equity transactions of RMB 1.5 billion，led by CPE, with funds from CICC Capital, Jimin Credential, Qingsong Capital, Pudong Science and Technology, Haier Medical, Ruiyi Investment and Lanshang Capital. Old shareholders Luxin Venture Capital, Shandong Transportation Development Fund and Xiantong Capital continued to increase their weight. Yikai Capital served as the exclusive financial advisor for this round of financing.

3D Medicines (3DMed), founded in 2010, is a leader in precision medicine in China dedicated to making early and personalized diagnosis accessible to each patient.

3DMed set the standard of innovation in automated molecular diagnostics and artificial intelligence (AI) to help physicians leverage genetic information to tailor treatment to individual patients.

In 2018, 3DMed introduced an AI-based cancer genome data interpretation system, the ANDiS Genome Insight. In late 2019, 3DMed launched the world’s first fully closed automated NGS library-prep system, the ANDiS 400. 3DMed aspires to be a game changer by offering a diverse pipeline of automated molecular diagnostics.

Soon after the coronavirus 2019 (COVID-2019) outbreak, 3DMed responded rapidly by developing a series of RT-qPCR-based tests (the ANDiS SARS-CoV-2 Detection Kit and the ANDiS SARS-CoV-2 & Influenza A/B Detection Kit) for qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens collected from individuals who meet the CDC criteria for SARS-CoV-2 testing.

CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world-class team of investment professionals and supported by over 200 domestic and international investors, the firm uses its sector expertise to generate deal flow and drive the value creation work during the post-investment stage.